Neuroendocrinology Articles
-
Protein Fusion Extends Drug Half-Life Technology
Protein fusion is a genetic recombination technique in which the DNA of an inactive peptide or protein chain segment to be grafted is recombined with the DNA of a drug and expressed together by engineered cells; no specialized grafting operations are required. In the current technology, the inactive peptide or protein chain segment used for protein fusion is the FC region of albumin and antibody. ...
-
Application of Capillary Electrophoresis Technology in Biopharmaceuticals
Capillary Electrophoresis (CE) is an analytical technique used in the development and quality control of protein drugs. From medium optimization, clone screening, formulation stability research and purification process monitoring, to protein characterization, related impurity detection, protein structure identification and protein drug product quality control, CE is required in all aspects of ...
-
Do Peptide Drugs Need Acylation Blocking at Nα?
The formation of 2,5-diketopiperazine (DKP) with a bicyclic structure is one of the most detrimental side reactions and degradation pathways affecting peptide synthesis. Despite its crucial role as a versatile building block in drug discovery, the formation of DKP reactions is highly undesirable in the production of peptide drugs. DKP formation can occur during the process of peptide drug ...
-
Applications of the High Polymers in Medical Science
Introduction With the wide application of high polymers, more and more extensive researches on high polymers have been conducted in recent years. Many papers and monographs discussed the important characteristics of high polymers and their important applications in medicine. Macromolecule/high polymers can be used in surgery, suture, orthopedic fixation and tissue repair. They can also be used as ...
-
Rani is Opening Doors in Biosimilars, Challenging Humira and Others
San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results, as well as several corporate updates. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity, which opens doors for significant developments in biosimilars. Rani has been on the radar of major life science investors for years. The company caught ...
-
Rani developing technology for oral delivery of injectable biologics
(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract. “This is not a new idea, although previous attempts were based on chemistry and ...
-
California Prop65 list
1. Tetrahydrocannabinol (THC) Tetrahydrocannabinol (THC) is an active ingredient in Nabiximols, a specific extract of Cannabis that was approved as a botanical drug in the United Kingdom since 2010 as a mouth spray for people with multiple sclerosis to reduce neuropathic pain, spasticity, overactive bladder, and other symptoms. Nabiximols (as Sativex) is available as a prescription drug in ...
-
Rani Therapeutics’ $73M IPO will fund upcoming clinical trials
Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday. According to S-1 filings, shares were estimated to price between $14 and $16 last week. On Friday, shares debuted slightly lower, around $11. Rani raised about $73 million in its debut. Rani’s debut comes amidst a flurry of IPO activity in therapeutics. In 2020, 71 ...
-
Rani Therapeutics offers breakthrough capsule for patients with chronic conditions
Rani Therapeutics offers a breakthrough capsule, the RaniPill which could change the way patients with chronic conditions take medication by eliminating the need for painful injections. Rani Therapeutics is a clinical-stage biotherapeutics company offering an alternative to painful injections for patients with chronic conditions such as neuroendocrine tumours(NETS). The company based in ...
-
Rani Therapeutics prices $73M IPO for robotic drug-delivery pill tech
Rani Therapeutics Holdings (NSDQ:RANI), developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million. The company initially targeted an IPO worth approximately $100 ...
-
LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency
Abstract Abstract Title: “LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency “Presentation Type: Oral Science Type and Topic: Clinical Trial Introduction: LUM-201 (ibutamoren, formerly MK-0677) is an orally administered GH-secretagogue that stimulates the GH secretagogue receptor (GHSR1a) in the hypothalamus and pituitary. LUM-201 ...
By Lumos Pharma
-
Punctuating messages encoded in human genome with transposable elements
San Francisco, CA - Since the classical studies of Jacob and Monod in the early 1960s, it has been evident that genome sequences contain not only blueprints for genes and the proteins that they encode, but also the instructions for a coordinated regulatory program that governs when, where and to what extent these genes and proteins are expressed. The execution of this regulatory code is what ...
-
A three‐generational study of in ovo exposure to PBDE‐99 in the zebra finch
Based on a literature review of avian data for polybrominated diphenyl ethers (PBDEs), ecologically relevant doses, low (10 ng/egg), medium (100 ng/egg), and high (1,000 ng/egg) of the 2,2',4,4',5‐pentabromodiphenyl ether (BDE‐99) congener along with dimethylsulfoxide (DMSO) control were injected into the yolk sac of un‐incubated eggs of zebra finch, Taeniopygia guttata. Offspring development ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you